Great insight mate, much appreciated.

First 29 Last

Share
Profile

Follow
pembo111

2,193 Posts.

5

22/10/15

17:22

Post #: 16232753
Share

Originally posted by Lefevre ↑

Yes, a great event today.

Red bar and I caught up with Tony Keating and Brian Leedman before lunch and after the preso.

I will outline a few comments below and Red bar I am sure will add to them later this evening.

The pre FDA meeting in the next month or so is a massive event and the FDA will outline exactly what is required for FDA approval. Their USA advisors already have a good feel and reckon that RAP are already well on the way to meet the anticipated guidelines. The first FDA approval will be for asthma and pneumonia. The testing results so far only support asthma and pneumonia. They have had results for other respiratory diseases but they haven't been large enough samples. Then within 90 days of that approval they can apply for bronchitis, hooping cough etc when they have had big enough samples which is less than 50. The FDA approval for the extra diseases will just be a formality.

Their FDA application is for a Class 2 medical device. They have to show safety and efficacy. There is obviously no safety issues ( its just a cough into a microphone). They only have to prove efficacy and it is felt anything above 90% is more than satisfactory. A GP is only 70 to 80% accurate and a specialist is 90% accurate. We are currently 97% accurate.

RAP has already had many approaches for licencing and partnerships but have them all on hold until after the pre FDA meeting as they want to maximise RAPs bargaining position. So, by the first quarter next year we should have some commercial deals outlined. The main target market is the Tele health providers in the US and they are talking about $5 to $10 per use. That is massive when 30% of all tele health visits are respiratory.

I get the impression that a WHO deal could be at anytime. The revenue model for WHO will be much cheaper and will be more a subscription model as they could possibly test thousands of people in a day.

The trial in Indonesia was with a Samsung and the trials in Australia are with an i phone. Tony feels the microphone from different phones is not an issue as they are all of excellent quality. The FDA approval will be for a microphone of a certain minimum bandwith which all phones will have. Interestingly the trials were all done in the emergency departments of the hospitals where outside noise is a big factor. The algorithim was not affected by any outside noise.

Keating and Leedman were not available at the booth for questions for most of the day as they were at meetings with fund managers. All the other booths were stocked and RAP's was empty.

It was a great day. Well worth attending.

Look forward to Red bar's comments later.

Expand

Great insight mate, much appreciated.

RAP Price at posting: 4.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

There are more pages in this discussion • 174 more messages in this thread...

First 29 Last

Add RAP (ASX) to my watchlist

(20min delay)
Last 20.5¢		Change 0.000(0.00%)		Mkt cap ! $176.2M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Great insight mate, much appreciated.

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Featured News

Great insight mate, much appreciated.

Top Stories

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Featured News

Featured News